MARKET

REPL

REPL

Replimune Group
NASDAQ
4.070
+0.730
+21.86%
After Hours: 4.250 +0.18 +4.43% 19:59 05/08 EDT
OPEN
3.320
PREV CLOSE
3.340
HIGH
4.180
LOW
3.300
VOLUME
15.13M
TURNOVER
--
52 WEEK HIGH
13.24
52 WEEK LOW
1.500
MARKET CAP
336.07M
P/E (TTM)
-1.1844
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-Replimune, uniQure rise after report FDA chief Makary may be ousted
Reuters · 1d ago
Replimune Climbs on Report of Makary's Possible Ouster From FDA
Dow Jones · 1d ago
Replimune jumps on news FDA chief behind RP1 rejection may be removed
TipRanks · 1d ago
BUZZ-Replimune surges after report FDA chief Makary may be ousted
Reuters · 1d ago
REPLIMUNE GROUP SHARES JUMP 21% AFTER REPORT TRUMP PLANNING TO FIRE FDA CHIEF MARTY MAKARY
Reuters · 1d ago
Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity
Seeking Alpha · 1d ago
FDA head Makary defends drug application rejections amid criticism
Seeking Alpha · 4d ago
What's Going On With Replimune Stock On Tuesday?
Benzinga · 4d ago
More
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Webull offers Replimune Group Inc stock information, including NASDAQ: REPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REPL stock methods without spending real money on the virtual paper trading platform.